Aims: To investigate the effects of erythropoietin (EPO) on the clinical outcomes of patients with acute ST segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
Material and methods: We collected randomized controlled studies conducted before April 15, 2017, and performed a meta-analysis using RevMan5.3 software.
Results: Compared with the conventional revascularization group, mortality (RR = 0.79; 95% Cl, 0.42 - 1.50; p = 0.47), stroke events (RR = 2.63; 95% Cl, 0.70 - 9.85; p = 0.15), recurrent myocardial infarction (RR = 0.99; 95% Cl, 0.44 - 2.20; p = 0.98), and other clinical endpoints were not significantly different in the EPO group. However, subgroup analysis showed a marginally significant difference between the high-dose EPO group and the control group (MD = 1.29; 95% CI, 0.02 - 2.56; p = 0.05) in ejection fraction.
Conclusion: The administration of EPO has no effects on the clinical outcomes of patients with acute STEMI after PCI, whilst a high dose of EPO may increase patients' ejection fraction. .